From Early Screening to Treatment: A Comprehensive Multidisciplinary Pathway Guide for Liver Cancer

Introduction

Liver cancer is often called the "silent killer" because it typically presents no obvious symptoms in its early stages, and many patients are already at an intermediate or advanced stage upon diagnosis. However, with advances in medicine, especially the widespread adoption of the multidisciplinary team (MDT) model, liver cancer treatment is no longer a "one-man show" by a single department. Instead, experts from hepatobiliary surgery, interventional radiology, medical oncology, radiology, and pathology collaborate to tailor the most appropriate treatment plan for each patient. For international patients, understanding this full pathway not only helps alleviate fear but also enables you to communicate effectively with doctors. This article will guide you step by step through the key milestones from diagnosis to treatment, starting with early screening.

Step 1: Who Needs Screening? Identifying High-Risk Groups

Liver cancer screening is not necessary for everyone, but the following groups are considered high-risk and are advised to undergo liver ultrasound and serum alpha-fetoprotein (AFP) testing every 6 months:

Carriers of hepatitis B or hepatitis C virus (especially those with long-term high viral load)

Patients with liver cirrhosis (regardless of etiology)

Individuals with a family history of liver cancer

Long-term heavy drinkers or those with non-alcoholic fatty liver disease (NAFLD)

In China, hepatitis B is the primary cause, with approximately 80% of liver cancer cases linked to the hepatitis B virus. If you fall into any of the above categories, do not overlook regular screening. Early-stage liver cancer (single tumor ≤3 cm) treated with surgery or ablation can achieve a 5-year survival rate of over 70%, whereas advanced-stage disease has a rate below 20%. These figures underscore that early screening is the first step in changing your fate.

Step 2: Confirming Diagnosis and Staging—Imaging, Pathology, and Liver Function Assessment

If screening detects a suspicious nodule, doctors will recommend further tests. Common modalities include:

Contrast-enhanced MRI or CT: Clearly visualizes tumor size, number, location, and vascular invasion, serving as the cornerstone for staging.

Contrast-enhanced ultrasound: Dynamically observes blood flow perfusion, aiding in differentiating benign from malignant lesions.

Liver biopsy: When imaging is atypical or genetic testing is needed, pathological tissue can be obtained to determine differentiation grade and molecular characteristics.

Additionally, liver function assessment (Child-Pugh grade) and performance status scoring (ECOG) are essential, as liver cancer patients often have concurrent cirrhosis, and liver function directly determines treatment tolerance. When seeking medical care internationally, please bring all previous medical records, imaging discs (in DICOM format), and laboratory reports to avoid redundant tests and expedite the diagnostic process.

Step 3: Multidisciplinary Team (MDT)—The Core of Personalized Care

The MDT approach serves as the "navigation system" for liver cancer treatment. At the top-tier tertiary hospitals in China partnered with Meijiakang, the MDT team typically comprises experts from hepatobiliary surgery, interventional radiology, medical oncology, radiation oncology, radiology, and pathology. They convene at fixed times each week to collectively discuss each patient's case and develop individualized plans, rather than leaving decisions to a single department head.

Key points of MDT discussion include:

Tumor staging (BCLC or CNLC staging) and assessment of resectability

Whether liver function reserve can tolerate surgery or interventional procedures

Suitability for systemic therapies such as targeted therapy or immunotherapy

Timing of radiotherapy and target volume design

For example, for early-stage resectable liver cancer, surgical resection is prioritized; however, if tumors are multiple or liver function is poor, radiofrequency ablation, microwave ablation, or liver transplantation may be chosen. For intermediate-stage disease, transarterial chemoembolization (TACE) combined with systemic therapy has become the mainstream approach. The value of MDT lies in avoiding "overtreatment" or "undertreatment" and integrating the indications of the latest drugs (e.g., lenvatinib, sintilimab).

Step 4: Detailed Treatment Pathways—From Local to Systemic

Based on staging, common treatment pathways are as follows:

Early stage (0-A): Surgical resection or local ablation (radiofrequency/microwave); if meeting Milan criteria, liver transplantation is also a curative option. Regular follow-up is required post-surgery to prevent recurrence.

Intermediate stage (B): TACE is the first choice, which can be combined with ablation or radiotherapy. In recent years, the "TACE + targeted therapy + immunotherapy" triple regimen has significantly extended survival, and some patients have gained opportunities for downstaging surgery.

Advanced stage (C): Systemic therapy is the mainstay, including targeted agents (lenvatinib, sorafenib) combined with immune checkpoint inhibitors (e.g., PD-1 inhibitors), or chemotherapy. If bone or brain metastases occur, localized radiotherapy should be added for pain relief or decompression.

All treatments require dynamic evaluation, with imaging and tumor marker tests recommended every 2-3 months to adjust the plan promptly. For international patients, I suggest establishing a personal electronic medical record documenting each treatment time, drug dosage, and side effects to facilitate remote consultations.

Step 5: Rehabilitation and Follow-Up—Preventing Recurrence Is Critical

The recurrence rate after liver cancer surgery exceeds 50%, with most recurrences occurring within 2 years post-surgery. Therefore, rehabilitation management is crucial:

Antiviral therapy: For hepatitis B-related liver cancer, long-term use of entecavir or tenofovir can reduce recurrence risk.

Lifestyle: Strictly abstain from alcohol, maintain a balanced diet, and appropriately supplement protein; avoid liver-protective drugs or herbal remedies of unknown composition to prevent additional liver burden.

Regular follow-up: For the first 2 years post-surgery, re-examine every 3 months, then every 6 months, including ultrasound, AFP, and liver and kidney function tests.

Psychological support should not be overlooked. Consider joining patient support groups or consulting a professional psychologist to maintain a positive mindset.

Recommendations for International Patients

If you or a family member is facing a liver cancer diagnosis, please keep the following points in mind:

Initiate MDT early: Do not delay due to hesitation. At Meijiakang, we can help you quickly connect with top-tier liver cancer MDT teams in China, typically completing multidisciplinary consultations within 3-5 working days.

Prepare complete materials: Include all raw imaging data, pathology reports, treatment history, and medication lists, as this significantly improves consultation efficiency.

Understand medical costs: Costs vary greatly by treatment modality—for example, surgery ranges from ¥50,000 to ¥100,000, TACE from ¥20,000 to ¥40,000 per session, and targeted therapy plus immunotherapy from ¥10,000 to ¥30,000 per month (depending on drug insurance policies). You can use our cost estimator tool for a personalized budget reference.

Leverage remote consultations: If you cannot travel to China immediately, you can first arrange a remote video consultation via contact us, where experts will provide preliminary recommendations before you decide whether to travel for treatment.

Although liver cancer is formidable, scientific diagnostic pathways and advanced multidisciplinary collaboration have enabled more and more patients to achieve long-term survival. Trust that standardized treatment is more reliable than folk remedies. We are here to accompany you every step of the way.